---
title: Comparative performance of scFv-based anti-BCMA CAR formats for improved T
  cell therapy in multiple myeloma
date: '2024-04-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38630291/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240417180658&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR
  T cells have emerged as a novel therapy with potential for long-term disease control.
  Anti-BCMA CAR T cells with a CD8-based transmembrane (TM) and CD137 (41BB) as intracellular
  costimulatory domain are in routine clinical use. As the CAR construct architecture
  can differentially impact performance and efficacy, the optimal construction of
  a BCMA-targeting CAR remains to be elucidated. Here, we hypothesized that varying
  ...
disable_comments: true
---
In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR T cells have emerged as a novel therapy with potential for long-term disease control. Anti-BCMA CAR T cells with a CD8-based transmembrane (TM) and CD137 (41BB) as intracellular costimulatory domain are in routine clinical use. As the CAR construct architecture can differentially impact performance and efficacy, the optimal construction of a BCMA-targeting CAR remains to be elucidated. Here, we hypothesized that varying ...